By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Schering AG 

Müllerstrasse 172- 178

Berlin    D-13342  Germany
Phone: 49-30-468-11-11 Fax: +49-30-468-15305





ILEX Oncology, Inc.  Together with Millennium Pharmaceuticals, Inc., ILEX has entered into a distribution and development agreement with Schering AG to market CAMPATH worldwide except for Japan and East Asia.

Collateral Therapeutics Inc.  A strategic collaboration to develop and commercialize cardiovascular gene therapy products to promote angiogenesis. GENERXTM is being evaluated in Phase 2b/3 clinical trials for stable angina. GENVASCORâ„¢ is being evaluated in Phase 1/2 clinical trials for peripheral vascular disease.

Affinimark Technologies Inc. 

Company News
Bayer AG (BAY) Determines EUR 98.98 As Cash Compensation Per Schering AG (SHR) Share 12/5/2006 10:38:16 AM
Schering AG (SHR) And Stanford University To Cooperate In The Field Of Molecular Imaging 11/28/2006 11:37:20 AM
Schering AG (SHR) Maintains Strong Growth Momentum During First Nine Months Of 2006 11/27/2006 10:02:29 AM
Schering AG (SHR) Release: Betaferon(R) Approved In Australia For Earliest Stages Of Multiple Sclerosis 11/27/2006 9:24:33 AM
Warner Chilcott Licenses Worldwide Rights To Schering AG (SHR)'s SEGRA Compound For Dermatologic Indications And Announces Settlement Of Yaz(R) Patent Litigation 11/14/2006 12:46:20 PM
Go-Ahead For Schering AG (SHR)'s Integration Into The Bayer Group 11/8/2006 12:53:13 PM
Entry In The Commercial Register; Agreement Between Bayer AG (BAY) And Schering AG (SHR) In Force, Resolution Of Schering Extraordinary Stockholders' Meeting Implemented 10/31/2006 11:34:00 AM
FDA Approves Berlex Inc.'s Betaseron(R) For Use After The First Event Suggestive Of Multiple Sclerosis 10/23/2006 11:27:50 AM
Schering AG (SHR) And Biogen Idec, Inc. (Massachusetts) (BIIB) Announce Start Of The ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin 10/5/2006 10:51:55 AM
FDA Approves New Indication For Berlex Inc.'s YAZ(R) To Treat Emotional And Physical Symptoms Of Premenstrual Dysphoric Disorder (PMDD) 10/5/2006 9:25:05 AM